Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials

OBJECTIVES: Fear of opioid withdrawal syndrome (OWS) often dissuades opioid discontinuation. Lofexidine is an FDA-approved, alpha(2)-adrenergic receptor agonist for treatment of OWS. Pivotal trial results from the per-protocol statistical analyses have been published. However, the FDA prescribing in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Danesh, Tirado, Carlos, Pirner, Mark, Clinch, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Addiction Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968526/
https://www.ncbi.nlm.nih.gov/pubmed/32002194
http://dx.doi.org/10.1080/21556660.2019.1704416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968526/
https://www.ncbi.nlm.nih.gov/pubmed/32002194
http://dx.doi.org/10.1080/21556660.2019.1704416

Ejemplares similares